Table 2

Baseline characteristics of tofacitinib-treated and tocilizumab-treated patients with RA, grouped by the status of previous bDMARD use, after propensity score matching

bDMARD-naïve patients (n=186)Previous bDMARD-failure patients (n=160)
Tofacitinib
(n=93)
Tocilizumab
(n=93)
P value*ASDTofacitinib
(n=80)
Tocilizumab
(n=80)
P value*ASD
Baseline characteristics
 Age, years, mean (SD)63.6 (13.7)64.5 (14.1)0.530.06565.4 (11.3)64.7 (10.0)0.540.066
 Male sex, number (%)20 (21.5)21 (22.6)1.000.02218 (22.5)17 (21.3)1.000.024
 RA duration, years, mean (SD)8.8 (10.4)8.3 (9.2)0.700.05111.9 (8.5)12.1 (9.0)0.840.023
 Advanced stages, number (%)31 (33.3)31 (33.3)1.00<0.00146 (57.5)46 (57.5)1.00<0.001
 Anti-CCP-positive, number (%)78 (83.9)76 (81.7)0.840.04772 (90.0)69 (86.3)0.610.092
 RF-positive, number (%)81 (87.1)79 (84.9)0.830.05167 (83.8)67 (83.8)1.00<0.001
 CDAI, mean (SD)22.7 (9.6)22.9 (10.6)0.890.02022.5 (10.6)23.2 (9.7)0.690.020
 High CDAI (>22), number (%)38 (40.9)41 (44.1)0.740.05336 (45.0)36 (45.0)1.00<0.001
Concurrent MTX use§, number (%)63 (67.7)53 (57.0)0.140.18§40 (50)54 (67.5)0.040.30§
Concurrent PSL use§, number (%)27 (29.0)48 (51.6)0.0050.38§28 (35.0)38 (47.5)0.140.21§
  • *Comparisons of each of the baseline characteristics between the tofacitinib and tocilizumab groups after propensity score matching, separately in bDMARD-naïve patients and bDMARD-failure patients, using the paired-sample t-test for continuous variables and the McNemar test for categorical variables.

  • †ASD of <0.10 indicates that the baseline characteristic was well balanced between the two treatment groups (tofacitinib vs tocilizumab).

  • ‡Advanced stages were defined as Steinbrocker radiological stages III and IV.

  • §Concurrent use of MTX and PSL was not used in propensity score matching because the use of these drugs was determined after the treatment selection.

  • anti-CCP, anti-cyclic citrullinated peptide antibodies; ASD, absolute standardised difference; bDMARD, biological disease-modifying antirheumatic drug; CDAI, clinical disease activity index; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; RF, rheumatoid factor.